Skip to main content

Table 1 Univariate analysis for the association of various clinicopathologica features with SAA expressions of patients with ovarian cancer

From: Serum amyloid a, a potential biomarker both in serum and tissue, correlates with ovarian cancer progression

Feature

N.(n = 100)

SAA [mg/L, M (QR)]

Z

P

Age(y)

  ≥ 60

55 (55%)

51.7 (15.63,187.95)

1.254

0.516

  < 60

45 (45%)

57.6 (18.35,180.7)

  

FIGO stage

 I-II

30 (30%)

8.8 (6.30,32. 3)

7.106

0.003

 III

25 (25%)

42.1 (12.8166.35)

  

 IV

45 (45%)

68.30 (22.63,187.95)

  

Histology subtype

 Serous

64 (64%)

8.8 (6.4,79.8)

−3.017

0.002

 Endometrioid

36 (36%)

55.8 (22.85,192.65)

  

Lymphatic invasion

 No

41 (41%)

17.7 (7.42,43.47)

−3.927

0.000

 Yes

59 (59%)

157.4 (66.43,216.6)

  

Distant metastasis

 NO

55 (55%)

13.60 (6.15,46.23)

−3.416

0.001

 Yes

45 (45%)

80.90 (29.23,211.03)

  

ER

 Positive

70 (70%)

27.90 (8.20,156.30)

0.810

0.418

 Negative

30 (30%)

17.40 (6.90,108.40)

  

PR

 Positive

39 (39%)

32.30 (6.85,136.60)

0.265

0.791

 Negative

61 (61%)

27.30 (7.70,136.00)